COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,044 Articles (22,627 medRxiv, 8,417 bioRxiv)

Most recent first Previous |  Page 3028: Articles 30271-30280  | Next

Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
Khan, S., Nakajima, R., Jain, A., de Assis, R. R., Jasinskas, A., Obiero, J. M., Adenaiye, O., Tai, S., Hong, F., Milton, D. K., Davies, H., Felgner, P. L., Prometheus Study Group
10.1101/2020.03.24.006544 — Posted: 2020-03-25 Discussion: Onsite
FEP-based screening prompts drug repositioning against COVID-19
Li, Z., Li, X., Huang, Y.-Y., Wu, Y., Zhou, L., Liu, R., Wu, D., Zhang, L., Liu, H., Xu, X., Zhang, Y., Cui, J., Wang, X., Luo, H.-B.
10.1101/2020.03.23.004580 — Posted: 2020-03-25 Discussion: Onsite
Computational analysis of SARS-CoV-2 S1 protein O-glycosylation and phosphorylation modifications and identifying potential target positions against CD209L-mannose interaction to inhibit initial binding of the virus
Uslupehlivan, M., Sener, E.
10.1101/2020.03.25.007898 — Posted: 2020-03-25
Potent human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, X., Wang, R., Yu, J., Shan, S., Zhou, B., Song, S., Tang, X., Yu, J., Ge, J., Lan, J., Yuan, J., Wang, H., Zhao, J., Zhang, S., Wang, Y., Shi, X., Liu, L., Wang, X., Zhang, Z., Zhang, L.
10.1101/2020.03.21.990770 — Posted: 2020-03-25 Discussion: Onsite | Offsite
Effect of SARS-CoV-2 infection upon male gonadal function: A single center-based study
Ma, L., Xie, W., Li, D., Shi, L., Mao, Y., Xiong, Y., Zhang, Y., Zhang, M.
10.1101/2020.03.21.20037267 — Posted: 2020-03-24 Discussion: Onsite
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
Bian, H., Zheng, Z.-H., Wei, D., Zhang, Z., Kang, W.-Z., Hao, C.-Q., Dong, K., Kang, W., Xia, J.-L., Miao, J.-L., Xie, R.-H., Wang, B., Sun, X.-X., Yang, X.-M., Lin, P., Geng, J.-J., Wang, K., Cui, H.-Y., Zhang, K., Chen, X.-C., Tang, H., Du, H., Yao, N., Liu, S.-S., Liu, L.-N., Zhang, Z., Gao, Z.-W., Nan, G., Wang, Q.-Y., Lian, J.-Q., Chen, Z.-N., Zhu, P.
10.1101/2020.03.21.20040691 — Posted: 2020-03-24 Discussion: Onsite | Offsite
MATHEMATICAL PREDICTIONS FOR COVID-19 AS A GLOBAL PANDEMIC
Victor, A. O.
10.1101/2020.03.19.20038794 — Posted: 2020-03-24
First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients
Chen, H., Zhang, Z., Wang, L., Huang, Z., Gong, F., Li, X., Chen, Y., WU, J. J.
10.1101/2020.03.22.20034041 — Posted: 2020-03-24 Discussion: Onsite
Infection Control of 2019 Novel Corona Virus Disease (COVID-19) in Cancer Patients undergoing Radiotherapy in Wuhan
Xie, C., Wang, X., Liu, H., Bao, Z., Yu, J., Zhong, Y., Chua, M. L.
10.1101/2020.03.21.20037051 — Posted: 2020-03-24
Characterizing occupations that cannot work from home: a means to identify susceptible worker groups during the COVID-19 pandemic
Baker, M. G.
10.1101/2020.03.21.20031336 — Posted: 2020-03-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).